CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab. Nisenbaum L, Martone R, Chen T, Rajagovindan R, et al. Alzheimers Dement 2023;19:3379-3388.

Read + Share

Amedeo Smart

Independent Medical Education

Nisenbaum L, Martone R, Chen T, Rajagovindan R, et al. CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab. Alzheimers Dement 2023;19:3379-3388.
PMID: 36795603